Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving patient trust and the overall viability of clinical trials.
Lori Ellis, head of insights at Biospace, and Elisa Cascade, CPO of Advarra discuss the challenges faced by clinical research sites at SCOPE 2025. Cascade highlights that many sites are reporting significant staff shortages of over 50%. This issue is expected to worsen. Since patient experience and trust are influenced by the sites, she suggests a “patient-centric” approach incorporates a “site-centric” approach.
Key Takeaways
- Staff shortages put sites in a disadvantaged position, making it harder for them to be patient-centric and build trust with patients.
- Improving “site-centricity” - focusing on the needs and challenges of clinical research sites - is crucial, as sites are the primary point of contact with patients in clinical trials.
- Two key gaps that could be addressed to help sites include streamlining the login process and improving the clinical trial startup process.
- There is a need for more collaboration and alignment across the industry to support clinical research sites and ensure the sustainability of the clinical research ecosystem.ALL COVERAGE
Jay Ferro, EVP, CIO, CPO & CTO at Clario discusses safety, trust and what keeps him up at night.
Continuing our SCOPE 2025 coverage, Rohit Nambisan, CEO at Lokavant addresses not only current challenges, but the life sciences industry’s responsibility to maintain scientific integrity.
Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving patient trust and the overall viability of clinical trials.
The industry remains unwavering in the commitment to increased clinical trial accessibility and representation.
As communication gaps in the US healthcare market widen, the emphasis on the need for credible information and patient empowerment is paramount.
While at SCOPE 2025, Sam Srivastava, CEO at WCG Clinical discusses the challenges and responsibilities of the life sciences industry in building public trust amidst growing anger towards healthcare.
In the current legal and political landscape, it is all about survival for DEI initiatives.
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
